Part VI: Summary of the risk management plan

Summary of risk management plan for Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension (Brinzolamide)

This is a summary of the risk management plan (RMP) for Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension. The RMP details important risks of Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension, how these risks can be minimised, and how more information will be obtained about for Brinzolamide 10 mg/ml Eye drops, suspension's risks and uncertainties (missing information).

Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension should be used.

Important new concerns or changes to the current ones will be included in updates of Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension's RMP.

I. The medicine and what it is used for

Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension is indicated for the following conditions:

Brinzolamide is indicated to decrease elevated intraocular pressure in:

- Ocular hypertension
- Open-angle glaucoma

as monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.

It contains brinzolamide as the active substance and it is for ocular use.

The data and conclusions included in this report are confidential and proprietary information of Marketing Authorisation Holder.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension, together with measures to minimise such risks and the proposed studies for learning more about Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension' risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed including PSUR assessment and signal management activity, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information

The data and conclusions included in this report are confidential and proprietary information of Marketing Authorisation Holder.

on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Important identified risks	• None
Important potential risks	• None
Missing Information	• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorization or specific obligation of Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Brinzolamide 10 mg/ml Eye drops, suspension & Brinzolamide Accord 10 mg/ml Eye drops suspension as post-authorisation development plan.

The data and conclusions included in this report are confidential and proprietary information of Marketing Authorisation Holder.